| Name | Title | Contact Details |
|---|
We are advocates, not just providers. Leading health plans and patients to better outcomes through a broad range of medication therapy management (MTM) programs. Empowering connections that matter. Mirixa is the leading provider of MTM and targeted, pharmacist-delivered services to health plans. An MTM pioneer, we`ve been building connections since 2006 - harnessing the knowledge and skills of pharmacists to engage more patients and deliver measureable results. We have the largest and most comprehensive pharmacy services network in North America. And we create leading edge programs that reach beyond Medicare Part D compliance, helping health plans of all types deliver a more focused patient experience and positive outcome, while potentially reducing total healthcare costs. Our goal is your goal: to ultimately empower every patient to live a fuller, healthier life.
Cogent Biosciences is a biotechnology company developing real solutions to treat genetically driven diseases. With a focus on rational drug discovery and development, we are leveraging validated biology to advance precision therapies designed to address the true underlying drivers of disease and provide real hope for patients. Cogent`s lead therapeutic candidate, PLX9486 (expected to be named CGT9486 in the future), is a precision kinase inhibitor designed to selectively and potently inhibit the KIT D816V mutation. This mutation is responsible for driving a rare and serious condition called Systemic Mastocytosis which can severely impact many different tissues and organs in the body. We are also studying PLX9486 to treat advanced gastrointestinal stromal tumors (GIST), which have a strong dependence on oncogenic KIT signaling.
hhoaltd is a Hinsdale, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
St. Patricks Hospital is a Missoula, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kadmon is a fully integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. We are developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. We leverage our multi-disciplinary research and clinical development team members, who prior to joining Kadmon had brought more than 15 drugs to market, to identify and pursue a diverse portfolio of novel product candidates, both through in-licensing products and employing our small molecule and biologics platforms. We utilize our advanced understanding of the molecular mechanisms of disease to establish development paths for disease areas where significant unmet medical needs exist.